The main goal of this study is to determine whether there is a relationship between
fremanezumab's ability to prevent migraine and improved sleep quality in migraine patients
(fremanezumab is a FDA-approved humanized CGRP monoclonal antibody for the treatment of
migraine).
This is a within-person study design that examines treatment effects (changes) using
high-resolution assessments. To complete the study, each participant will be observed using
daily assessments of migraine and sleep outcomes before treatment (baseline: 0 to 30 days),
and at 1, 2, and 3 months after treatment (injection 1: days 31-60, injection 2: days 61-90,
injection 3: days 91-120). In essence, this creates an interrupted time-series design where
repeated interventions are introduced at fixed intervals.